Literature DB >> 17266049

Bradykinin analogs containing the 4-amino-2-benzazepin-3-one scaffold at the C-terminus.

S Ballet1, R De Wachter, K Van Rompaey, Cs Tömböly, D Feytens, G Töth, L Quartara, P Cucchi, S Meini, D Tourwé.   

Abstract

High affinity peptide ligands for the bradykinin (BK) B(2) subtype receptor have been shown to adopt a beta-turn conformation of the C-terminal tetrapeptide (H-Arg(1)-Pro(2)-Pro(3)-Gly(4)-Phe(5)-Ser(6)-Pro(7)-Phe(8)-Arg(9)-OH). We investigated the replacement of the Pro(7)-Phe(8) dipeptide moiety in BK or the D-Tic(7)-Oic(8) subunit in HOE140 (H-D-Arg(0)-Arg(1)-Pro(2)-Hyp(3)-Gly(4)-Thi(5)-Ser(6)-D-Tic(7)-Oic(8)-Arg(9)-OH) by 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one templates (Aba). Binding studies to the human B(2) receptor showed a correlation between the affinities of the BK analogs and the propensity of the templates to adopt a beta-turn conformation. The L-spiro-Aba-Gly containing HOE140 analog BK10 has the best affinity, which correlates with the known turn-inducing property of this template. All the compounds did not modify basal inositolphosphate (IP) output in B(2)-expressing CHO cells up to 10 microM concentration. The antagonist properties were confirmed by the guinea pig ileum smooth muscle contractility assay. The new amino-benzazepinone (Aba) substituted BK analogs were found to be surmountable antagonists.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266049     DOI: 10.1002/psc.827

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  5 in total

1.  Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.

Authors:  Steven Ballet; Debby Feytens; Koen Buysse; Nga N Chung; Carole Lemieux; Suneeta Tumati; Attila Keresztes; Joost Van Duppen; Josephine Lai; Eva Varga; Frank Porreca; Peter W Schiller; Jozef Vanden Broeck; Dirk Tourwé
Journal:  J Med Chem       Date:  2011-03-17       Impact factor: 7.446

2.  Azepinone-Containing Tetrapeptide Analogues of Melanotropin Lead to Selective hMC4R Agonists and hMC5R Antagonist.

Authors:  Olivier Van der Poorten; Krisztina Fehér; Koen Buysse; Debby Feytens; Ioanna Zoi; Steven D Schwartz; José C Martins; Dirk Tourwé; Minying Cai; Victor J Hruby; Steven Ballet
Journal:  ACS Med Chem Lett       Date:  2014-12-03       Impact factor: 4.345

3.  Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist - neurokinin-1 antagonist peptidomimetics.

Authors:  Karel Guillemyn; Patrycia Kleczkowska; Anna Lesniak; Jolanta Dyniewicz; Olivier Van der Poorten; Isabelle Van den Eynde; Attila Keresztes; Eva Varga; Josephine Lai; Frank Porreca; Nga N Chung; Carole Lemieux; Joanna Mika; Ewelina Rojewska; Wioletta Makuch; Joost Van Duppen; Barbara Przewlocka; Jozef Vanden Broeck; Andrzej W Lipkowski; Peter W Schiller; Dirk Tourwé; Steven Ballet
Journal:  Eur J Med Chem       Date:  2014-12-19       Impact factor: 6.514

4.  Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffold.

Authors:  Steven Ballet; Alexander V Mayorov; Minying Cai; Dagmara Tymecka; Kevin B Chandler; Erin S Palmer; Karolien Van Rompaey; Aleksandra Misicka; Dirk Tourwé; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2007-02-09       Impact factor: 2.823

5.  Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.

Authors:  Karel Guillemyn; Joanna Starnowska; Camille Lagard; Jolanta Dyniewicz; Ewelina Rojewska; Joanna Mika; Nga N Chung; Valérie Utard; Piotr Kosson; Andrzej W Lipkowski; Lucie Chevillard; Pol Arranz-Gibert; Meritxell Teixidó; Bruno Megarbane; Dirk Tourwé; Frédéric Simonin; Barbara Przewlocka; Peter W Schiller; Steven Ballet
Journal:  J Med Chem       Date:  2016-04-14       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.